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G-protein-coupled receptors (GPCRs) are typically
present in a basal, inactive state but, when bound
to an agonist, activate downstream signaling cas-
cades. In studying arrestin regulation of opioid
receptors in dorsal root ganglia (DRG) neurons, we
find that agonists of delta opioid receptors (dORs)
activate cofilin through Rho-associated coiled-coil-
containing protein kinase (ROCK), LIM domain
kinase (LIMK), and b-arrestin 1 (b-arr1) to regulate
actin polymerization. This controls receptor func-
tion, as assessed by agonist-induced inhibition of
voltage-dependent Ca2+ channels in DRGs. Agonists
of opioid-receptor-like receptors (ORL1) similarly
influence the function of this receptor through
ROCK, LIMK, and b-arr1. Functional evidence of
this cascade was demonstrated in vivo, where the
behavioral effects of dOR or ORL1 agonists were
enhanced in the absence of b-arr1 or prevented by
inhibiting ROCK. This pathway allows dOR and
ORL1 agonists to rapidly regulate receptor function.
INTRODUCTION
The neuronal cytoskeleton provides both the 3D structural stabil-
ity critical for cellular function and the infrastructure that allows
the cell to respond to external stimuli. Dynamic remodeling
of the cytoskeleton, particularly of the actin filaments, provides
the network along which intracellular proteins may be trafficked
as needed. This mechanism allows proteins to be shuttled to and
from the synapse and allows the Golgi apparatus to sort and1010 Cell Reports 5, 1010–1021, November 27, 2013 ª2013 The Auttraffic newly synthesized proteins to the cell membrane (Lowe,
2011; Salvarezza et al., 2009). Proteins bound for the cell mem-
brane from the Golgi may be either constitutively exported
through a specific pathway with specialized secretory vesicles
that are formed and move continuously along the microtubules
or secreted on demand. A dynamic actin cytoskeleton plays an
important role in this process; both the actin-severing protein
cofilin, and the upstream kinase LIMK, have been shown to
inhibit or facilitate the release of specific proteins from the Golgi
to the cell membrane (Egea et al., 2006; Heimann et al., 1999;
Salvarezza et al., 2009).
Similar to many other membrane proteins, newly synthesized
G-protein-coupled receptors (GPCRs) are sorted, processed,
degraded, or trafficked from the endoplasmic reticulum to the
Golgi. Thereafter, GPCR transfer through the Golgi stack is com-
plex and may involve several escort or chaperone proteins to
release the receptor to the cell membrane. For the most part,
the rate of GPCR release to the cell membrane is determined
by the quality-control mechanisms within the endoplasmic retic-
ulum, and once within the Golgi, GPCRs are presumed to be
constitutively released to the cell membrane. By regulating the
number of GPCRs released to the cell membrane, this bio-
synethetic pathway may influence receptor availability and sig-
naling (Achour et al., 2008; Dong et al., 2007).
b-arrestin 1 or 2 recruitment to the protease-activated recep-
tor 2 (PAR2) regulates chemotaxis by binding with and activating
cofilin and associated regulatory proteins. This alters actin turn-
over within the leading and trailing edges of the cell in order to
facilitate cell migration (DeFea, 2007; Xiao et al., 2010; Zoudilova
et al., 2007, 2010). In examining b-arrestin 1 (b-arr1) regulation
of GPCR function in dorsal root ganglia (DRG) neurons, we
have found that this arrestin isoform influences the stability of
the actin cytoskeleton to rapidly control the magnitude of
GPCR signaling.hors
Figure 1. dOR and ORL1 Function Is Enhanced in Dorsal Root
Ganglia Neurons Lacking b-arr1
(A) The whole-cell patch-clamp technique was used to examine VDCC inhi-
bition by Go/i coupled receptors. DPDPE, a peptidergic dOR agonist, and
nociceptin, an ORL1 agonist, demonstrated enhanced VDCC coupling in
b-arr1/ versus b-arr1+/+ DRG neurons, whereas VDCC inhibition by agonists
of the mu receptor, DAMGO and morphine (1 mM ea), the GABAB receptor,
baclofen (50 mM), and the a2A receptor, clonidine (10 mM), was not different
across genotypes.
(B) Further analysis of dOR-VDCC inhibition showed enhanced dOR inhibition
of VDCCs by the nonpeptidergic dOR agonist, SNC80, in medium (shown by
the arrow), but not small, early postnatal medium-sized b-arr1/ versus
b-arr1+/+ DRG neurons in the SvEv129SJ background. Scale bar = 10 mm.
(C) The concentration response curve demonstrated enhanced efficacy and
potency of SNC80 in b-arr1/ versus b-arr1+/+ neurons (p < 0.001).
Cell ReRESULTS
The primary afferent neurons of the DRGs, the first-order
neurons of the analgesic pathway, relay nociceptive information
from the peripheral to the central nervous system. In addition to a
number of Gi/o-coupled GPCRs, these neurons also express
the nonvisual arrestins (Komori et al., 1999). Of the two iso-
forms, b-arrestin 2 is known to regulate the function of some
Gi/o-coupled GPCRs in DRG neurons (Tan et al., 2009; Walwyn
et al., 2007). However, whether b-arr1 regulates the function of
these GPCRs has not been established.
b-arr1 Modulates VDCC Inhibition by Some GPCRs
As agonists of Gi/o-coupled GPCRs can inhibit voltage-
dependent Ca2+ channels (VDCC), the whole-cell patch-clamp
technique was used to assess b-arr1 regulation of Gi/o-coupled
GPCRs in DRG neurons. Of the five GPCRs examined, we found
that VDCC inhibition by the dOR agonist, DPDPE (p < 0.05 versus
b-arr1+/+), and the ORL1 agonist, nociceptin (p < 0.001 versus
b-arr1+/+), was enhanced in cells lacking b-arr1. On the other
hand, VDCC inhibition by agonists of the mu opioid and
GABAB and a2A adrenergic receptors was not altered (Figure 1A).
Further analysis of the dOR-VDCC profile showed that, in addi-
tion to the peptidergic agonist, DPDPE, the nonpeptidergic
and arguably more selective dOR agonist, SNC80 (1 mM), also
resulted in greater VDCC inhibition in medium-sized, but not
small, DRG neurons lacking b-arr1 (p < 0.001 versus b-arr1+/+;
Figure 1B). The concentration-response curve of SNC80 in
medium-sized neurons demonstrated enhanced efficacy and
potency of this dOR agonist in b-arr1/ neurons (Emax;
b-arr1+/+; 32.1 ± 3.1, b-arr1/; 47.7% ± 2.5% inhibition, p <
0.001; Figure 1C). This enhanced inhibition was receptor
specific; it was reversed by the delta antagonist naltrindole
(NTI; SNC80 and NTI applied at 1 mM; b-arr1+/+; 0.1% ± 0.6%,
b-arr1/; 1.1% ± 1.8% inhibition). It was also reversed by the
ORL1 antagonist, JTC801 (JTC801 and nociceptin at 1 mM:
b-arr1+/+; 1.6% ± 7.1%, b-arr1/; 6.3% ± 5.1%). Medium-sized
neurons frommice of different ages or backgrounds showed the
same profile of enhanced inhibition in b-arr1/ neurons (p < 0.05
versus b-arr1+/+; Figures 1D and 1E), which could not be
explained by basal changes in Ca2+ channel density, the relative
proportion of N-, P/Q-, and L-type Ca2+ channels present, or
constitutive dOR-VDCC coupling (Figure S1).
b-arr1 Regulation of dOR Desensitization
As dORs recruit b-arr1 or b-arr2 and show less desensitization in
cells lacking b-arr1 (Qiu et al., 2007), the enhanced efficacy of(D) Similar to neurons from mice backcrossed into the SvEv129SJ back-
ground, medium-sized DRG neurons from early postnatal b-arr1/ in the
C57Bl/6 background showed enhanced SNC80-VDCC inhibition.
(E) Similar to early postnatal DRG neurons, medium-sized DRG neurons from
adult mice showed increased SNC80-VDCC inhibition in b-arr1/ versus
b-arr1+/+ neurons.
All data are shown as mean ± SEM. *p < 0.05 versus b-arr1+/+; **p < 0.001
versus b-arr1+/+; ***p < 0.001 versus b-arr1+/+; n = 6–27 per data point. All
exemplar currents depict the current before (1), during (2), and after (3) agonist
application, and the scale bars show time (20 ms) on the x axis and current on
the y axis (5 or 10 nA) for early postnatal or adult DRG neurons, respectively.
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Figure 2. b-arr1 Regulates dOR Desensiti-
zation and Internalization, but This Does
Not Explain the Enhanced dOR-VDCC
Coupling in b-arr1/ Neurons
(A) Rapid desensitization. Once complete inhibi-
tion of VDCCs was obtained by SNC80, further
perfusion with SNC80 desensitized this inhibition.
This is shown by the decline in the peak current
amplitude over 120 s in the left panels. Although
both b-arr1+/+ and b-arr1/ neurons desensitized,
b-arr1/ neurons showed less desensitization.
**p < 0.01; n = 5–10.
(B) Acute desensitization. Whereas preincubation
of DRGs with 50 and 500 nM SNC80 for 10 min
desensitized dOR-VDCC inhibition at all time
points in +/+ neurons, / neurons did not
desensitize after 10 min of 50 nM SNC80 but
desensitized thereafter and showed equivalent
desensitization at all time points when pre-
incubated with 500 nM SNC80. b-arr1+/+: a, b,
and c: p < 0.05 versus untreated; d and e: p <
0.0001 versus untreated; f: p < 0.001 versus un-
treated. b-arr1/: b: p < 0.001 versus untreated;
c: p < 0.001 versus untreated; d, e, f: p < 0.0001
versus untreated; n = 6–7 per data point. Columns
in shades of gray, Bi; +/+ or Bii; /, indicate data
shown in Figure 1.
(C) Internalization assessed by flow cytometry in
b-arr1/ and b-arr1+/+ DRG neurons using an
N-terminal antibody and allophycocynanin (APC)-
conjugated secondary antibody. (i) The dOR-
labeled nonfixed samples were initially sorted by
size (FSC-H) and granularity (SSC-H) to select
the medium-large DRG neurons (>25 mM in
diameter; Walwyn et al., 2004). APC-labeled
dORs were then selected after removing
nonspecific background labeling and all samples
of each experiment analyzed by these parame-
ters. (ii) Although basal cell surface dOR levels
were unaffected by the b-arr1/ deletion, 50 and
500 nM SNC80, but not 1,000 nM SNC80,
increased cell surface dOR levels in barr1/
DRGs. #p < 0.05 versus untreated b-arr1/; *p <
0.05 versus b-arr1+/+, same time point; n = 4–8
per data point.
(D) A slower rate of internalization could enhance
dOR-VDCC inhibition by increasing the number
of dORs on the plasma membrane. This was
assessed by overexpressing cerulean (CFP)-
labeled dORs (Walwyn et al., 2009). This increased
dOR-VDCC inhibition equally in both b-arr1+/+
and b-arr1/ neurons tested with either DPDPE
or SNC80 (1 mM ea). *p < 0.05, **p < 0.01, and
***p < 0.001 versus b-arr1+/+; #p < 0.05 and ## p <
0.01 versus endogenous dORs; n = 6–18 per data
point. All exemplar currents depict the current
before, during, and after agonist application (1, 2, and 3) and the scale bars show time (20 ms) and current (5 nA) on the x and y axes, respectively. Columns in
dark (b-arr1+/+) or light (b-arr1/) shades of gray indicate data shown in Figure 1. All data are shown as mean ± SEM.dOR agonists in b-arr1/ neurons could be a result of attenu-
ated desensitization. This was assessed in vitro by rapid desen-
sitization, in which an agonist is continually perfused while
dOR-VDCC inhibition ismonitored, and by acute desensitization,
in which the cells are preincubated with SNC80, washed, and
dOR-VDCC inhibition assessed. Both measures showed a geno-
type effect (Figures 2A and 2B). First, rapid desensitization1012 Cell Reports 5, 1010–1021, November 27, 2013 ª2013 The Autoccurred in both b-arr1/ and b-arr1+/+ neurons, but this was
less in b-arr1/ neurons (p < 0.01 versus b-arr1+/+; Figure 2A).
Second, acute desensitization, involving preincubation with 50
or 500 nM of SNC80 for 10, 30, or 60 min, followed by a 1 mM
SNC80 test dose, showed delayed desensitization after 10 min
of 50 nM SNC80 in barr1/ neurons but equivalent desensitiza-
tion thereafter and no difference in the amount or rate ofhors
Figure 3. b-arr1 Control of Protein Export Explains Enhanced
dOR-VDCC Inhibition
The increase in cell surface receptor number after 50 and 500 nM SNC80
(Figure 2C) could reflect b-arr1 control of dOR release to the plasma mem-
brane. This was assessed by inhibiting protein export. (i) DRGs were pre-
treated with brefeldin A (Bref. A; 1 mg/ml 30 min pretreatment) to inhibit protein
release from the endoplasmic reticulum and Exo1, a more specific inhibitor of
protein release from the Golgi (0.8 and 3.2 mg/ml, included in the intracellular
recording solution). Both brefeldin A and Exo1 (0.8 mg/ml) reduced the
enhanced SNC80 inhibition of VDCCs in b-arr1/ to b-arr1+/+ levels, but the
higher dose of Exo1 (3.2 mg/ml) reduced SNC80-inhibition in both/ and +/+
neurons. (ii) Exo1 did not affect GABAB-VDCC inhibition, assessed by baclofen
(50 mM).
All data are shown as mean ± SEM. #p < 0.05 versus untreated b-arr1+/+
or b-arr1/. ***p < 0.001 versus b-arr1+/+; n = 6–12 per data point All exemplar
currents depict the current before, during, and after agonist application
(1, 2, and 3) and the scale bars show time (20 ms) and current (5 nA) on the
x and y axes, respectively. Columns in dark (b-arr1+/+) or light (b-arr1/)
shades of gray indicate data shown in Figure 1.
Cell Redesensitization induced by 500 nM SNC80 (Figure 2B). In
summary, we found that dOR desensitization was delayed in
b-arr1/ neurons. However, when compared with dOR-VDCC
inhibition, which reached a maximum within 20–40 s of agonist
exposure, the attenuated desensitization, seen by 120 s of
continual agonist perfusion, cannot explain the enhanced
dOR-VDCC inhibition seen in b-arr1/ neurons.
b-arr1 Regulation of dOR Internalization
As the arrestins are known to initiate internalization, deleting
b-arr1 could delay dOR internalization to increase cell surface
receptor number and enhance dOR function. Internalization
was examined by flow cytometry using an allophycocyanin-
labeled antibody to the N terminus of the dOR, the specificity
of which was confirmed in cells lacking dORs (Figure S2). The
nonfluorescent parameters of size and granularity were then
used to gate on medium- to large-sized neurons (Figure 2Ci;
Walwyn et al., 2004). These cells showed no effect of genotype
on basal cell surface receptor levels (b-arr1/: 89.9 ± 4.0 of
b-arr1+/+ levels). However, after 10 min of 50 and 500 nM
SNC80, but not 1 mM SNC80, cell surface receptor levels
were increased in b-arr1/ (p < 0.05 versus untreated
b-arr1/), but not b-arr1+/+, neurons (p < 0.05 versus
b-arr1+/+; Figure 2Cii). After 1 hr of SNC80 (1 mM), virally ex-
pressed cerulean-labeled dORs expressed in b-arr1+/+ and
b-arr1/ neurons demonstrated significant internalization (Fig-
ure S3). As dORs are dynamically trafficked to and from the cell
membrane, the initial increase in dORs on the cell membrane
could reflect delayed internalization and/or enhanced external-
ization in b-arr1/ neurons (Cahill et al., 2007; Walwyn et al.,
2009).
Accumulation of dORs on the Cell Membrane Does
Not Account for the Enhanced dOR Function in b-arr1/
Neurons
Attenuated internalization or enhanced externalization would
lead to an accumulation of receptors on the cell membrane, so
explaining the increase in dOR-VDCC coupling in b-arr1/
neurons. Lentiviral expression of cerulean-tagged (CFP) dORs
was therefore used to overexpress dORs in b-arr1/ and
b-arr1+/+ neurons. This did increase dOR-VDCC inhibition,
assessed by either 1 mMDPDPE or 1 mMSNC80 (p < 0.05 versus
endogenous levels; Figure 2D). However, the increase occurred
equally in b-arr1+/+ and b-arr1/ neurons, suggesting that
dOR-VDCC inhibition is sensitive to altered receptor number
but that the regulatory role of b-arr1 remains even when these
receptors are overexpressed (p < 0.05 versus b-arr1+/+).
b-arr1 Control of Protein Export Explains the Enhanced
dOR-VDCC Inhibition
Because flow cytometric analysis showed a greater number of
dORs on the cell membrane, it is possible that b-arr1 controls
dOR release to the cell membrane in an agonist-dependent
manner. This was tested by preincubating cells with brefeldin
A, an inhibitor of protein export. This reduced dOR-VDCC inhibi-
tion in b-arr1/ neurons to b-arr1+/+ levels with no effect in +/+
neurons at this concentration (p < 0.05 versus untreated
b-arr1/; Figure 3i). A more specific inhibitor of protein exportports 5, 1010–1021, November 27, 2013 ª2013 The Authors 1013
from the Golgi, Exo1 (0.8 mg/ml), reduced dOR-VDCC inhibition
in b-arr1/ neurons and, when used at a higher concentration
(3.2 mg/ml), reduced dOR-VDCC inhibition in both b-arr1+/+ and
b-arr1/ neurons (p < 0.05 versus untreated; Figure 3ii). To
probe for nonspecific effects, GABAB-VDCC was examined in
the presence of ExoI, but no effect was found (Figure 3iii). As
dOR-VDCC inhibition is closely correlated with cell surface re-
ceptor levels (Walwyn et al., 2005), these data could be inter-
preted as an Exo1-mediated inhibition of dORs released to the
cell membrane in an agonist-dependent manner.
dOR Activation of Cofilin Is b-arr1 Dependent
Both LIMK and cofilin are required for the export of specific pro-
teins from the Golgi to the cell membrane (Salvarezza et al.,
2009; vonBlume et al., 2009). dORs could activate cofilin to regu-
late receptor export via this pathway and to affect receptor
function. dOR activation of the phosphorylated, inactivated
form of cofilin was assessed in mouse embryonic fibroblasts
(MEFs). MEFs were chosen for this assay because they express
or lack the necessary proteins of this pathway (b-arr1, ROCK,
LIMK, and cofilin) and have been used to study arrestin-GPCR
signaling (Zoudilova et al., 2010). This pathway is also conserved
in DRGs (Ahmed et al., 2011). In wild-type MEFs, we found that
SNC80 (1 mM) reduced the amount of phosphorylated cofilin
in b-arr1/ (2–30 min; p < 0.01 or 0.01 versus untreated
b-arr1+/+), but not in b-arr1+/+, MEFs. Together, these data
show that SNC80 activates cofilin in a b-arr1-dependent manner
(Figure 4A).
ROCK, LIMK, and b-arr1 Regulation of dOR-VDCC
Coupling
Given that b-arr1 is known to bind with and regulate LIMK
(Zoudilova et al., 2007) and LIMK has been shown to control
the export of specific proteins from the Golgi (Salvarezza
et al., 2009), it is possible that dOR export and therefore func-
tion may be regulated by b-arr1. We examined this possibility
by inhibiting ROCK, the kinase responsible for phosphorylating
and activating LIMK, in neurons containing or lacking b-arr1.
The ROCK inhibitor Y27632 decreased dOR-VDCC inhibition
in both b-arr1/ and b-arr1+/+ neurons (p < 0.01 versus
untreated b-arr1+/+; p < 0.001vs untreated b-arr1/; Figure 4B)
but had no effect on GABAB-VDCC coupling (untreated:
b-arr1+/+; 49.8% ± 5.3%, b-arr1/: 46.6% ± 3.4%, Y27632
(400 ng/ml); b-arr1+/+; 49.5% ± 2.2%, b-arr1/: 51.1% ±
2.5%). We then used an approach designed to enhance
LIMK activity by including excess LIMK (1 and 2 mg/ml) within
the intracellular recording solution. The 2 mg/ml dose increased
dOR-VDCC coupling in both b-arr1+/+ and b-arr1/ neurons
(p < 0.05 versus untreated b-arr1+/+ or b-arr1/; Figure 4B),
demonstrating that LIMK influence dOR-VDCC inhibition.
Because LIMK phosphorylation of cofilin can be inhibited by
the serine 3 LIMK peptide (Aizawa et al., 2001), we included
this peptide in the intracellular recording solution (S3; 1.6
and 6.4 mg/ml). This reduced dOR-VDCC inhibition in b-arr1/
neurons (p < 0.001 versus untreated b-arr1/), but not in
b-arr1+/+ neurons (Figure 4B). Together, these data suggest
that dOR-VDCC inhibition may be regulated by ROCK, LIMK,
and b-arr1.1014 Cell Reports 5, 1010–1021, November 27, 2013 ª2013 The AutActin Polymerization Influences dOR-VDCC Inhibition
LIMK has been shown to phosphorylate and inhibit cofilin to
stabilize the actin cytoskeleton in dendritic spines (Shi et al.,
2009). It is possible that LIMK, b-arr1, and cofilin could similarly
regulate the stability of the actin ‘‘tracks’’ required for the export
of dORs to the cell membrane. The ability of actin polymerization
to affect dOR-VDCC inhibition was therefore examined by
manipulating actin polymerization minutes before assessing
dOR-VDCC inhibition. First, we stabilized the actin cytoskeleton
by including jasplakinolide and thymosin b4 within the intracel-
lular recording solution (Bubb et al., 1994; Huff et al., 2001).
This increased dOR-VDCC inhibition in b-arr1+/+ neurons to
b-arr1 levels but had no effect in neurons (p < 0.05 versus un-
treated b-arr1+/+; Figure 4C). Preventing polymerization by
including latrunculin B (LatB, 200 ng/ml; Morton et al., 2000)
within the intracellular recording solution reduced the enhanced
dOR-VDCC inhibition in b-arr1/ neurons to b-arr1+/+ levels
without affecting GABAB-VDCC inhibition (p < 0.05 versus un-
treated b-arr1/; Figure 4C). Together, these data demonstrate
that manipulations designed to influence actin polymerization
can regulate SNC80-VDCC inhibition.
ORL1-VDCC Inhibition Is Similarly Controlled by b-arr1,
ROCK, LIMK, and Actin Polymerization
The previous experiments used dORs as a model GPCR to
examine each component of this regulatory pathway. Because
ORL1-VDCC inhibition was upregulated in b-arr1/ neurons,
we next examined whether, similar to dORs, ORL1-VDCC may
be controlled by this ROCK-LIMK pathway in a b-arr1-
dependent manner. We assessed the effect of inhibitors of this
pathway (Y27632 [400 ng/ml], S3 [6.4 mg/ml], or LatB [200 nM])
on ORL1-VDCC coupling in b-arr1/ and b-arr1+/+ DRG
neurons. These three compounds reversed the enhanced
ORL1-VDCC inhibition in / neurons (p < 0.001 versus
untreated b-arr1/) but had no effect in +/+ neurons (Figure 4D).
These data suggest that ORL1-VDCC coupling may be
controlled by ROCK, LIMK, and actin polymerization in the
absence of b-arr1/.
Basal F-actin Incorporation Appears Unchanged
Because deleting b-arr1 could alter basal LIMK and cofilin activ-
ity, this could affect actin turnover throughout the cell. This was
assessed by the incorporation of Atto-647N phalloidin (30 nM,
10 min) in living DRG neurons that were then fixed and analyzed
by stimulated emission depletion (STED) microscopy. No effect
of genotype on phalloidin incorporation was observed in either
the neuronal cell bodies or processes of b-arr1/ versus
b-arr1+/+ neurons, suggesting that basal actin polymerization
was not altered in b-arr1 DRGs (Figure S4).
Behavioral Assays Provide Functional Evidence for
the Role of ROCK and b-arr1 in Regulating dOR
and ORL1 Function
dOR
Two well-known behavioral assays of dOR function, locomotion
and analgesia, were used to assess the function of this pathway.
In the open-field test of locomotion, SNC80 (3 mg/kg adminis-
tered subcutaneously [s.c.]) increased the locomotor activity ofhors
Figure 4. dOR and ORL1 Inhibition of VDCCs
Is Regulated by LIMK, ROCK, and Actin
Polymerization
(A) The dOR agonist, SNC80, activates cofilin. Wild-
type MEFs (WT MEFs) or b-arr1/ MEFs were treated
with SNC80 for 0–120 min and lysates analyzed by
western blot. (i) Representative western blots of phos-
phorylated cofilin (pcof) and total cofilin (tcof) in WT
MEFs (upper two panels) and b-arr1/ MEFs (lower
two panels) after SNC80 treatment. (ii) SNC80 (1 mM)
decreased phosphocofilin after 2, 5, 15, and 30 min in
WT MEFs (closed circles), whereas b-arr1/ MEFs
(open circles) showed no change. Values on the y axis
represent phosphocofilin normalized to basal levels at
each time point shown on the x axis. A: p < 0.001;
b: p < 0.01; c: p < 0.01 versus untreated WT MEFs.
(B) The ROCK inhibitor, Y27632 (200 and 400 ng/ml),
reduced dOR-VDCC coupling in b-arr1/ and b-arr1+/+
neurons. Although excess LIMK (2 mg/ml) increased
SNC80-VDCC inhibition in both b-arr1 +/+ and b-arr1/
neurons, SNC80-VDCC inhibition remained higher in
b-arr1/ neurons. LIMK phosphorylation of cofilin can
be prevented by the serine 3 peptide. This decreased
SNC80-VDCC inhibition in b-arr1/ neurons, but not
b-arr1+/+ neurons (S3: 1.6 and 6.4 ng/ml).
(C) (i) Jasplakinolde and thymosin B4 (200 ng/ml),
enhancers of actin polymerization, increased SNC80-
VDCC inhibition in b-arr1+/+ to b-arr1/ levels, whereas
latrunculin B (LatB; 200 ng/ml), an inhibitor of actin
polymerization, reversed the increased dOR-VDCC
inhibition in b-arr1/ to b-arr1+/+ levels. (ii) LatB did not
alter GABAB-VDCC inhibition assessed by baclofen
(50 mM).
(D) The increase in ORL1-VDCC inhibition in b-arr1/
DRG neurons was reversed by the ROCK inhibitor,
Y27632 (400 ng/ml), the LIMK inhibitory peptide, S3
(6.4 ng/ml), and latrunculin B (200 ng/ml). No effect of
these manipulations was seen in +/+ neurons.
All data are shown as mean ± SEM. *p < 0.05 and ***p <
0.001 versus b-arr1+/+; ##p < 0.01 or ###p < 0.001
versus untreated, matched genotype; n = 6–12 per data
point. All exemplar currents depict the current before,
during, and after agonist application (1, 2, and 3) and
the scale bars show time (20 ms) and current (5 nA) on
the x and y axes, respectively. Columns in dark
(b-arr1+/+) or light (b-arr1/) shades of gray indicate
data shown in Figure 1.
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b-arr1+/+ mice 20 min after the injection. This was reversed by
both the ROCK inhibitor (Y27632; 1 mg/kg administered intra-
peritoneally [i.p.]) and the delta antagonist, NTI (2 mg/kg s.c.,
p < 0.001 locomotion 3 treatment; Figure 5Ai). In contrast,
b-arr1/ mice showed an enhanced locomotor effect of
SNC80 seen both as a more rapid onset, occurring within
10 min of the SNC80 injection, and lasting considerably longer
than in wild-type littermates (p < 0.001 versus b-arr1+/+). Similar
to +/+ mice, this was reversed by Y27632 and NTI (p < 0.001
locomotion 3 treatment; Figure 5Aii). To assess whether this
inhibitory profile of Y27632 was due to nonspecific suppression
of locomotor behavior, we tested the effect on Y27632 on the
locomotor effects of fentanyl, a specific mu opioid receptor
agonist. Fentanyl (0.4 mg/kg s.c.) induced an equal hyperloco-
motor response in both genotypes that was not altered by
Y27632 (1 mg/kg i.p.; Figure S5A). No gender-based differences
in locomotion were observed in the SNC80-treated (p =
0.69 locomotion3 gender) or fentanyl-treated (p = 0.54 locomo-
tion 3 gender) groups.
In the second behavioral test of dOR function, the analgesic
effect of SNC80 was assessed by mechanical pain, in which
the number of paw withdrawals from ten applications of a 2 g
von Frey filament wasmeasured.We found that basal thresholds
were not influenced by genotype and that wild-type mice
showed a brief analgesic effect of SNC80 at the 20 min (p <
0.05 response 3 treatment), but not 40 min, time point
(5mg/kg s.c.; Figure 5Bi). In comparison, b-arr1/mice showed
enhanced analgesia or fewer responses 20 and 40 min after
SNC80 (p < 0.001 response 3 treatment). This effect of SNC80
was reversed by Y27632 (1.5 mg/kg) and NTI (4 mg/kg;
Figure 5Bii).
SNC80 produced some analgesia in naive wild-type mice (Fig-
ure 5Bi), but because chronic inflammatory pain results in
enhanced dOR analgesia in wild-type mice (Pradhan et al.,
2013), we next examined the role of ROCK in modulating dOR
function in inflammatory pain. We injected saline or Y27632
(10 mg/kg i.p.) prior to injecting complete Freund’s adjuvant
(CFA; 10 ml) in the left hind paw of wild-type mice and at 12 hr
intervals thereafter. After 48 hr, we assessed the effect of
SNC80 (1 and 5 mg/kg s.c.) on the mechanical pain threshold
in the Y27632- and saline-treated groups. We found thatFigure 5. dOR Behaviors Are Regulated by b-arr1 and LIMK
(A) Two behavioral assays were used to assess dOR function. (i) Locomotion. b-arr
SNC80 (3 mg/kg s.c., p < 0.001, F5,28 = 13.125, locomotion 3 treatment) that w
antagonist, naltrindole (2 mg/kg s.c.). b-arr1/mice also showed a hyperlocomo
was enhanced (p < 0.001, F1,9 = 25.79 versus b-arr1
+/+), occurred more rapidly tha
the duration of the test (90 min). This was similarly reversed by both Y27632 and n
the y axis. The blue arrow represents the second of the two injections. The bar g
(B) Mechanical analgesia was measured by the number of responses out of a tota
the right hindpaw. b-arr1+/+ mice showed a small effect of SNC80 (5 mg/kg s.c.,
6.525), but not the 40 min, time point. b-arr1/ mice, on the other hand, sho
administration (p < 0.001, F2,37 = 43.37, response 3 treatment). Y27632 (b-arr1
+/
(b-arr1+/+: p < 0.01 versus SNC80, b-arr1/: p < 0.001 versus SNC80) reversed
(C) We have previously shown that complete Freund’s adjuvant (CFA) induced ch
(p < 0.001, F1,25 = 114.17 versus baseline) in adult C57Bl6/J mice. This decrease
can be reversed by SNC80 (1or 5 mg/kg s.c.; p < 0.001, F1,23 = 33.84 threshold 3
injecting CFA, and at 12 hr intervals thereafter, did not alter the resultant hyperalg
(1 and 5 mg/kg; *p < 0.05 versus vehicle, ###p < 0.001 versus CFA). All data are
Cell ReY27632 reduced the ability of SNC80 to relieve the mechanical
hyperalgesia associated with chronic inflammatory pain (p <
0.05 versus vehicle; Figure 5C), highlighting the involvement of
ROCK in the functional upregulation of dORs seen in this model.
We also assessed whether genetic background influenced the
b-arr1 phenotype. Mice backcrossed to the C57Bl/6 back-
ground and lacking b-arr1 showed a similar enhanced response
to SNC80 in both locomotor and acute pain studies (Figures S5B
and S5C). Furthermore, this effect of SNC80 in b-arr1/ mice
was specific to b-arr1; SNC80-induced locomotion was similar
in b-arr2/, b-arr2+/+, and b-arr1+/+ mice (Figure S5B).
ORL1
We assessed the role of this pathway in modulating ORL1 func-
tion by measuring the locomotor effect of the ORL1 agonist, Ro
65-6570. This agonist is similar to Ro 64-6198, which has been
shown to either induce hypolocomotion or have no locomotor
effect in wild-type mice (Shoblock, 2007). Although wild-type
mice showed no effect of Ro 65-6570 (1.5 mg/kg i.p.), b-arr1/
mice showed a hypolocomotor response (p < 0.05 locomotion3
treatment), which was reversed by both Y27632 (0.5 mg/kg) and
the ORL1 antagonist, J-113397 (p < 0.05 versus Ro 65-6570;
Figure 6). Together, these data show enhanced ORL1 function
in b-arr1/ mice that can be reversed by inhibiting ROCK.
DISCUSSION
In being able to scaffold with cofilin, the inactivating kinase,
LIMK, and activating phosphatase, slingshot (SSL) or chrono-
phin, arrestins can control the activity of cofilin to influence actin
polymerization (Condeelis, 2001; Xiao et al., 2010; Zoudilova
et al., 2007, 2010). This pathway enables a dynamic remodeling
of the actin cytoskeleton in response to a chemotactic stimulus
(Nishita et al., 2005) and, as we show here, modulates the func-
tion of some GPCRs; i.e., dOR and ORL1.
A Model of the Pathway
Based on GPCR inhibition of Ca2+ channels, a voltage-
dependent and Gbg-mediated response that modulates neuro-
transmitter release, we propose the following model (Figure 7).
Under normal or wild-type conditions, agonist binding to
an agonist such as the dOR activates cofilin through the1+/+ mice showed a hyperlocomotor response to subcutaneously administered
as reversed by both the ROCK inhibitor (Y27632 1 mg/kg i.p.) and the delta
tor effect of SNC80 (p < 0.001, F5,26 = 31.19 locomotion3 interaction), but this
n the wild-type mice (p < 0.001, F17,153 = 4.051 versus b-arr1
+/+), and lasted for
altrindole. The data show time (min) on the x axis and distance traveled (cm) on
raphs depict the total locomotion over time.
l of ten applications of the same von Frey filament (2 g) to the plantar surface of
p < 0.05, F3,39 = 3.388, response 3 treatment) at the 20 min (p < 0.01, F3,39 =
wed a greater response at both the 20 and 40 min time points after SNC80
+: p < 0.01 versus SNC80, b-arr1/: p < 0.001 versus SNC80) and naltrindole
the antinociceptive effect of SNC80 in both b-arr1+/+ and b-arr1/ mice.
ronic pain decreases the mechanical threshold in the von Frey test of allodynia
is associated with a functional upregulation of dORs (Pradhan et al., 2013), as it
treatment) in wild-type mice. Administration of Y27632 (10 mg/kg i.p.) prior to
esia (p = 0.563, F1,25 = 0.34 versus vehicle) but did inhibit the effect of SNC80
shown as mean ± SEM.
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Figure 6. ORL1 Behavioral Responses Are
Similarly Regulated by b-arr1 and LIMK
The bioavailable ORL1 agonist, Ro 65-6570
(1.5 mg/kg i.p.), did not alter the locomotor profile
of b-arr1+/+ mice (p = 0.54, F3,23 = 0.721 locomo-
tion 3 treatment) but induced a hypolocomotor
response in b-arr1/ mice. This was reversed by
Y27632 (p < 0.05, F3,28 = 3.027 locomotion 3
treatment). Data are shown as the total locomotor
response following the injection of vehicle
(vehicle), Ro 65-6570, or Y27632-Ro 65-6570
(Y27632-Ro 65) during the 45 min test period. All
data are shown as mean ± SEM. ***p < 0.001
versus other treatment groups.RhoA-ROCK-LIMK pathway. However, as b-arr1 is associated
with LIMK and one of the cofilin phosphatases such as SSL
(Xiao et al., 2010; Zoudilova et al., 2010), an enhanced but local
activation of cofilin occurs. We propose that this results in
controlled severing of F-actin and measured actin turnover to
regulate the stability of a subset of actin filaments within the
Golgi. This in turn controls the rate of export of dOR-containing
cargo vesicles from the Golgi to the cell membrane to allow a
limited response to a dOR agonist such as SNC80 (Figure 7A).
In the absence of b-arr1, SNC80 similarly activates LIMK through
the Rho-ROCK pathway, but without the regulatory control of
b-arr1, cofilin is not dephosphorylated and activated by SNC80
(Lin et al., 2003). We propose that this leaves stable actin tracks
in place, resulting in enhanced export of dORs from the Golgi to
the plasmamembrane to enhance dOR function (Figure 7B). This
pathway can be blocked by inhibiting ROCK, the kinase
responsible for phosphorylating LIMK and inactivating cofilin.
In preventing agonist-induced activation of this pathway, we
propose that agonist-induced turnover of a subset of actin
filaments within the Golgi does not occur and additional recep-
tors are not released to the cell membrane. Without this activa-
tion, the functional effect of the agonist is severely limited
(Figure 7C).
dOR Trafficking and Function
dOR-VDCC inhibition is a rapid, voltage-dependent cascade that
can be completely reversed by a high-voltage prepulse (data not
shown). We have previously found that dOR-VDCC inhibition is
positively correlated with dOR cell surface receptor levels
(Walwyn et al., 2005). Furthermore, increased dOR-VDCC
coupling is associated with enhanced dOR function (Pradhan
et al., 2013) and, conversely, reduced dOR function is associated
with reduced cell surface receptor levels (Scherrer et al., 2006).
Together, this suggests a close relationship between cell surface
receptor levels and dOR functionality, assessed either in vitro or
in vivo. The data presented here suggest that the ROCK-LIMK-
b-arr1 pathway is a critical mediator of this relationship and is
required to obtain an initial functional response. Thereafter, the
cooperative roles of b-arr1 in both desensitizing and modulating
dOR trafficking may further regulate dOR signaling.
ORL1 Function
Similar to dORs, our data suggest that b-arr1 also regulates
ORL1 function in a ROCK-, LIMK-, and actin-dependent manner.1018 Cell Reports 5, 1010–1021, November 27, 2013 ª2013 The AutHowever, this regulation is not evident in wild-type mice. It could
be that ROCK, LIMK, and b-arr1 inhibit ORL1 function to non-
detectable levels in wild-type neurons and mice. This is
suggested from the low levels of ORL1-VDCC coupling in wild-
type neurons (Figure 1) and the lack of a locomotor response
to the ORL1 agonist used (Figure 6). Interestingly, ORL1 function
has often been described in association with a pharmacological
or behavioral stimulus (Bebawy et al., 2010; Shoblock, 2007),
suggesting that this receptor, similar to dORs, may be upregu-
lated under certain conditions.
Other Receptors or Channels that May Be Regulated by
b-arr1, Cofilin, and LIMK
This fine-tuned control of actin polymerization to affect dOR and
ORL1 function may similarly control ligand-dependent activation
of other GPCRs such as dopamine receptor 1, neurotensin, or
PAR2, which are recruited from intracellular stores to the cell
membrane ‘‘upon demand’’ (Brismar et al., 1998; Hein et al.,
1994; Perron et al., 2006). Interestingly, many of these receptors
share a common postendocytic fate of being degraded once
internalized, suggesting that regulating the rate of receptor
release may be important to allow sufficient GPCR activation.
In providing a ligand-dependent spatiotemporal regulation of
actin filaments, b-arr1 may also regulate the function of ligand-
gated ion channels that may be rapidly trafficked to and from
the synapse upon demand.
Other Regulators of the Pathway
Wehave examinedGPCR activation of this pathway, but it is also
possible that other receptors or molecules may be involved. For
example, bradykinin or arachidonic acid has been shown to
enhance dOR function (Patwardhan et al., 2005; Pettinger
et al., 2013; Rowan et al., 2009). As kinins are involved in the
hyperalgesic response to chronic pain (Ferreira et al., 2002), it
is possible that bradykinin may activate this pathway in the
CFA model of chronic pain.
Conclusions
Following agonist-receptor activation of downstream signaling
cascades, GPCRs typically desensitize, becoming unable to
induce the same signaling profile. In contrast, we have found
that agonist binding with select GCPRs results in a functional
upregulation of the receptor. This increases GPCR-Ca2+ channel
inhibition and agonist-mediated behaviors, demonstrating howhors
Figure 7. b-arr1 Regulation of GPCR Function
(A) b-arr1+/+. In neurons containing b-arr1, the dOR agonist, SNC80, binds with
dORs and activates ROCK. Because b-arr1 is associated with LIMK and one of
the phosphatases (possibly SSL) within the trans-Golgi network (TGN), this
activates cofilin to enhance actin filament severing and turnover to regulate
dOR release to the cell membrane. PM, plasma membrane.
(B) b-arr1/. Without the inhibitory control of b-arr1, LIMK phosphorylates
and inactivates cofilin. This leaves stable actin tracks in place to allow
unregulated but agonist-dependent dOR release to the plasma membrane in
an agonist-dependent manner.
(C) Y27632. Preventing ROCK phosphorylation of LIMK by applying Y27632
prevents dOR activation of the pathway and agonist-induced release of dORs
to the cell membrane.this regulatory pathway allows these receptors to maintain or
enhance receptor function.
EXPERIMENTAL PROCEDURES
Animals
All animal experiments were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals and followed institutionally approved
animal care and use protocols. Mice lacking the b-arr1 (Conner et al., 1997)
or dOR (Filliol et al., 2000) were fully backcrossed into the 129S6/SvEv or
C57Bl/6 background. All animals used for the cellular experiments were
bred from homozygous matings within one generation of heterozygous
matings. For the behavioral experiments, 2- to 3-month-old equally distributed
males and females were generated from heterozygous matings. Unless noted
otherwise, all experiments used the 129S6/SvEv barr1 line.Cell ReCompounds
Unless otherwise noted, all chemicals were obtained from Sigma, except
for Y27632 (Selleckchem), SNC80, Naltrindole, ICI 174-864, Nociceptin,
J113397, JTC801 (R&D Systems), S3 (Anaspec), and LIMK (Cytoskeleton).
Dorsal Root Ganglion Neuron Cultures
DRGs were harvested from early postnatal (p0–1) mice or adult (6- to 8-week-
old) mice. The DRGswere enzymatically and physically dissociated and plated
in different formats and densities for different experiments. For electrophysi-
ology experiments, 5 3 104 dissociated cells were plated on poly-D-lysine-
coated (Sigma) and laminin-coated (Becton Dickenson) coverslips (10 mm
diameter) in the center of 35 mm MatTek dishes. Lentiviral transduction was
performed at the time of plating by adding 50 ng p24/plate to each plate.
For flow cytometry experiments, 13 106 cells were plated in a similarly coated
15 mm MatTek dish. The cells were cultured in 2 ml of Neurobasal A, B27,
GlutaMAX (0.5 mM), and antibiotic-antimycotic (12 U/ml) media (Life
Technologies) containing nerve growth factor (10 mg/ml, Roche) and kept at
37C and 5% CO2. Electrophysiological assessment of endogenous dOR
function was performedwithin 24 hr of plating, and for those inwhich receptors
were overexpressed, 72–96 hr thereafter. Flow cytometry was performed
within 48 hr of plating.
Electrophysiology
The whole-cell patch-clamp technique was used to record voltage-dependent
Ca2+ channel (VDCC) activity from DRG neurons (Axopatch 200A amplifier,
Molecular Dynamics) as previously described (Walwyn et al., 2007). At the
time of recording, the culture medium was replaced by an external solution
that contained (in mM) 130 TEA-Cl, 10 CaCl2, 5 HEPES, 25 D-glucose, and
2.5 3 104 tetrodotoxin (pH 7.2). Recording electrodes contained (in mM)
105 CsCl, 40 HEPES, 5 D-glucose, 2.5 MgCl2, 10 EGTA, 2 Mg
2+-ATP, and
0.5 Na+-GTP (pH 7.2). Ca2+ currents were activated by depolarizing neurons
from 80 mV to 10 mV for 100 ms at 20 s intervals. Recordings that exhibited
marked rundown were discarded. Stable recordings were fitted by a linear
function to compare, by extrapolation, control current amplitude to the current
amplitude recorded in the presence of the agonist. Data are expressed as
mean ± SEM and were compared using ANOVA with a post hoc Scheffe´ test.
Cofilin Dephosphorylation
Wild-type MEFs or barr1/ MEFs were treated with SNC80 for 0–120 min,
lysed, and analyzed by SDS-PAGE followed by western blotting with
antibodies to phosphocofilin (rabbit polyclonal, 1:1,000; Cell Signaling) or total
cofilin (mousemonoclonal, 1:500; BD Biosciences) and analyzed as previously
described (Zoudilova et al., 2007). The data are expressed as themean ±SEM,
and differences between groups were determined by one-way ANOVA (Prism
v5.03) with significance accepted at p < 0.05.
Flow Cytometry
After 48 hr in vitro, b-arr1+/+ and b-arr1/ or dOR+/+ and dOR /DRG neurons
were harvested and processed for dOR fluorescent labeling in nonfixed cells
using a primary antibody to the N terminus of the dOR (MBL) and an
allophycocyanin (APC)-conjugated secondary antibody (BD Biosciences) as
previously described (Walwyn et al., 2009). The data are expressed as the
mean ± SEM, and differences between groups were determined by one-way
ANOVA or paired Student’s t test with significance accepted at p < 0.05
(Analyze-it Software).
Behavioral Tests
Two- to 3-month-old b-arr1/ and b-arr1+/+ littermates of both genders were
used for the following behavioral effects.
Locomotion
Because SNC80 is known to increase locomotor behavior, this effect was
measured after 30 min of habituation to the test environment and the response
to SNC80 15 min after the injection of the dOR antagonist naltrindole, the
ROCK inhibitor Y27632, or vehicle, delivered s.c. or i.p., and measured over
the following 90 min. This behavior was recorded in 27 3 27 cm plastic boxes
by live tracking using an infrared camera and Ethovision XT (Noldus). Because
ORL1 agonists can induce a hypolocomotor response, this effect was testedports 5, 1010–1021, November 27, 2013 ª2013 The Authors 1019
by injecting a bioavailable ORL1 agonist, Ro 65-6570 (1.5 mg/kg i.p.) after
15 min of habituation and for the following 45 min. The ROCK inhibitor
Y27632, the ORL1 antagonist J-113397, or vehicle was injected 15 min prior
to Ro 65-6570.
Mechanical Pain
After 2 days of habituation to the test environment, the number of responses
(defined as a lifting or shaking of the paw upon stimulation of the plantar
surface), out of a total of ten repetitions, to the 2 g von Frey filament was
measured. Basal responses to the 2 g filament were acquired prior to the
injections, and the effect was tested 20 and 40 min thereafter.
CFA
Wild-type mice were habituated for 3 days prior to obtaining the basal
mechanical threshold by the up/down method (Chaplan et al., 1994). Saline
or Y27632 (10 mg/kg i.p.) was injected prior to assessing the basal response,
prior to the CFA injection (10 ml in the left hind paw), and at 12 hr intervals
thereafter. After 48 hr, the mechanical pain threshold was assessed and the
effect of SNC80 (1 and 5 mg/kg s.c.) determined. Data are expressed as
mean ± SEM, and differences between groups were analyzed by
ANOVA with repeated-measures and factorial analysis at each time point
(Stat View v5).
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